Organisation paid for research Program year 2025 Source: CMS Open Payments

Sarcoma Oncology Center

Neither a doctor nor a teaching hospital

Research payments

$2,407,504

113 payments

Through program year 2025, Sarcoma Oncology Center is reported as receiving $2,407,504 in research payments, across 113 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$756,935	61
2024	Research	$799,361	9
2023	Research	$368,785	8
2022	Research	$99,706	8
2021	Research	$546	1
2020	Research	$80,660	5
2019	Research	$301,512	21

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim Pharmaceuticals, Inc. $1,746,124 72 payments
Merck Sharp & Dohme Corporation $276,922 3 payments
Bayer HealthCare Pharmaceuticals Inc. $179,820 18 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $137,740 16 payments
E.R. Squibb & Sons, L.L.C. $62,000 1 payment
Sanofi US Services Inc. $3,786 2 payments
Boehringer Ingelheim International GmbH $1,113 1 payment

Studies the money was for Research payments · program years 2019–2025

Brightline-4 $628,338 3 payments
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma $431,462 22 payments
Phase I BI907828 in advanced TP53WT MDM2 amplified $292,571 6 payments
A P1,2 dose escal,expan to evaluate PYX-201 and Pembro in Adv solid tumors $157,320 1 payment
Phase I Brigimadlin advanced TP53WT/MDM2-amplified tumors $129,279 3 payments
A Randomized, Open-Label, Phase 2 Trial of CMB305 Sequentially Administered LV305 and G305 and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 $119,602 2 payments
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors $119,114 29 payments
BAY1217389 MPS1 Inh FU (Imidazo) $115,535 2 payments
Phase I Abemaciclib + BI 836845 $79,510 5 payments
BAY1436032 IDH Solid Tumors Ph1 FIM $64,285 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.